What is HC Wainwright’s Forecast for Nuvalent Q2 Earnings?

Nuvalent, Inc. (NASDAQ:NUVL) – HC Wainwright dropped their Q2 2026 earnings per share estimates for shares of Nuvalent in a note issued to investors on Monday, November 17th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($1.48) per share for the quarter, down from their prior estimate of ($1.31). HC Wainwright has a “Buy” rating and a $155.00 price target on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent’s Q3 2026 earnings at ($1.43) EPS, Q4 2026 earnings at ($1.19) EPS and FY2026 earnings at ($5.62) EPS.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same period in the previous year, the firm posted ($1.28) EPS.

Other equities analysts have also recently issued reports about the company. Barclays set a $152.00 price target on Nuvalent in a research report on Monday. Robert W. Baird raised their target price on Nuvalent from $112.00 to $158.00 and gave the stock an “outperform” rating in a research note on Tuesday. The Goldman Sachs Group upped their price target on Nuvalent from $120.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday. Guggenheim increased their price target on shares of Nuvalent from $125.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Cantor Fitzgerald started coverage on shares of Nuvalent in a research note on Wednesday, October 15th. They set an “overweight” rating and a $135.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $137.69.

Nuvalent Trading Down 3.5%

Nuvalent stock opened at $104.24 on Wednesday. The firm has a 50 day simple moving average of $89.11 and a 200 day simple moving average of $81.25. Nuvalent has a 1-year low of $55.53 and a 1-year high of $112.53. The firm has a market capitalization of $7.58 billion, a price-to-earnings ratio of -19.59 and a beta of 1.31.

Hedge Funds Weigh In On Nuvalent

Hedge funds and other institutional investors have recently modified their holdings of the company. Woodline Partners LP increased its position in shares of Nuvalent by 18.3% during the 3rd quarter. Woodline Partners LP now owns 1,069,520 shares of the company’s stock valued at $92,492,000 after purchasing an additional 165,288 shares during the last quarter. Alyeska Investment Group L.P. grew its position in Nuvalent by 102.1% during the third quarter. Alyeska Investment Group L.P. now owns 101,066 shares of the company’s stock valued at $8,740,000 after acquiring an additional 51,066 shares during the last quarter. Verition Fund Management LLC purchased a new position in shares of Nuvalent during the third quarter worth approximately $493,000. Vestal Point Capital LP lifted its holdings in shares of Nuvalent by 2.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,100,000 shares of the company’s stock worth $95,128,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Polar Capital Holdings Plc boosted its stake in shares of Nuvalent by 25.3% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,022,225 shares of the company’s stock valued at $88,402,000 after purchasing an additional 206,138 shares in the last quarter. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Deborah Ann Miller sold 21,800 shares of the firm’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $103.16, for a total transaction of $2,248,888.00. Following the sale, the insider owned 49,086 shares in the company, valued at approximately $5,063,711.76. This trade represents a 30.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO James Richard Porter sold 27,000 shares of Nuvalent stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $90.63, for a total transaction of $2,447,010.00. Following the sale, the chief executive officer directly owned 249,062 shares of the company’s stock, valued at $22,572,489.06. This represents a 9.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 246,071 shares of company stock valued at $22,589,016 in the last 90 days. 10.20% of the stock is owned by company insiders.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.